cyrilzakka/clinical-trials huggingface dataset:
Accurate Point of Care Liver Disease Diagnostics

This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. The investigators are testing a new technology to evaluate the liver (LiverScope®), and they will compare it to other methods to evaluate the liver, including advanced conventional liver MR and liver FibroScan® ultrasound exams. MR exams and FibroScan® ultrasound exams are common exams used to monitor NAFLD. Conventional MR scanners use magnetic fields and radio waves to make pictures of the liver. LiverScope® is a small, portable MR-based device that uses similar, but simplified technology, and can be used on top of an exam table in an outpatient setting. LiverScope® currently is not approved for clinical use.

In this study the investigators will learn how LiverScope® measurements of the liver compare to MR.

Study participants will be asked to complete a one-time visit which includes:

* LiverScope exam
* MR exam
* FibroScan exam (optional)
* Blood draw
* Completion of study questionnaires


Eligibility Criteria:
Inclusion Criteria:

* Age:18 years or older
* Known or clinically suspected NAFLD
* Weight less than 350 lbs (safety limit of MR scanner table)
* Able to lie on LiverScope® diagnostic table for about 15 min
* Able to hold breath repeatedly for about 20 s during MR and LiverScope® exams
* Willing and able to undergo all study procedures

Exclusion Criteria:

* VA patient only; not a UCSD patient
* UCSD or Livivos study personnel
* MR contraindication(s)
* Potential participant states that she knows that she is pregnant, thinks she may be pregnant or states she is trying to become pregnant\*
* Known chronic liver disease other than NAFLD
Safety and Effects of Ramipril Combined With Candesartan

we hypothesized that combination therapy has additive beneficial effects to improve endothelial dysfunction and adipocytokine profiles in patients with hypertension.

Forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16 mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled cross-over trial with three treatment arms and two washout periods (each 2 months).

Eligibility Criteria:
Inclusion Criteria:

* patients with mild to moderate hypertension

Exclusion Criteria:

* We will exclude patients with severe hypertension, unstable angina, acute myocardial infarction, or renal insufficiency.
Deep Brain Stimulation for the Treatment of Obesity

The purpose of this clinical study is to investigate the safety and efficacy of deep brain stimulation (DBS) as a treatment option for obesity.

The purpose of this clinical study is to investigate the safety and efficacy of deep brain stimulation (DBS) as a treatment option in the management of severe, treatment refractory, morbid obesity.

Eligibility Criteria:
Inclusion Criteria:

* At least 24 months post Roux-en-Y gastric bypass surgery without evidence of a sustained improvement in BMI after gastric bypass surgery for at least 6 months.
* Participant is willing to comply with all follow-up evaluations at the specified times
* Participant is able to provide informed consent
* Fluent in English

Exclusion Criteria:

* Medical contraindications for general anesthesia, craniotomy, or DBS surgery
* Evidence of neurological disorders, e.g., multiple sclerosis, Parkinson's disease and ischemic stroke, or severe brain atrophy or the presence of subdural hygromas or subdural hematomas.
* Severe cardiovascular, pulmonary, renal, liver, hematological disease, severe coagulopathy, acute infectious process
Examining the Effectiveness of the FaCES Adolescent SBIRT Intervention

The study will utilize a stepped wedge cluster randomized design to examine the effectiveness of the full FaCES (Facilitating Change for Excellence in SBIRT) adolescent SBIRT change package. Primary care providers will be randomized as to when they receive training and begin delivery of FaCES with their 12 to 17 year old patients, which includes targeted feedback based on the patient's endorsed substance use level on the S2BI screening instrument.

The study will utilize a stepped wedge cluster randomized design to examine the effectiveness of the full FaCES (Facilitating Change for Excellence in SBIRT) adolescent change package for 12 to 17 year old primary care patients. Primary care providers at two rural federally qualified health centers in New Mexico and Tennessee will be randomized as to when they receive training and begin delivering FaCES to their adolescent patients. FaCES includes targeted feedback based on the patient's endorsed substance use level on the S2BI screening instrument. Study participants will complete a baseline and follow-up assessment 3-months post study recruitment.

Eligibility Criteria:
Inclusion Criteria:

* Ages 12 to 17 years, inclusive
* Registered patient at one of the participating FQHCs
* Able and willing to provide informed consent

Exclusion Criteria:

* Inability to comprehend the assent form
* Parent/guardian declines consent
Thalamic LFPs and VIM DBS in Essential Tremor: Correlation, Evolution, and Therapeutic Perspectives

The objective of this study is to characterize through spectral analysis intra-thalamic local field potentials (LFPs) recorded through implanted DBS leads during periods with and without tremor in patients suffering from severe essential tremor.

Essential tremor (ET) is one of the most common adult movement disorders with a prevalence of 4% in the general population. Although several medications (primidone, beta-adrenergic blockers, benzodiazepines...) are commonly used, few of them are truly effective for controlling the severe forms of ET. Since 1987, an alternative has emerged with the development of high frequency deep brain stimulation (DBS) of the thalamic nucleus ventralis intermedius (VIM). This surgical technique now represents the gold standard treatment for tremor-disabled ET patients. Although VIM-DBS is clearly effective for treatment of essential tremor (ET) a partial loss of DBS effectiveness may occur over time in some patients. This loss of DBS effectiveness could be related to an adaptation of the local neuronal network to chronic stimulation (changes in synaptic plasticity). In order to avoid this problem, investigators plan to develop a intermittent mode of VIM stimulation using a new Medtronic device combining a DBS system with local field potential (LFPs) sensing capability. First, investigators propose to analyse VIM LFPs in order to define a tremor biomarker in 10 patients operated for severe ET. Thereafter, investigators will automatically detect this biomarker using a specific algorithm and use it to trigger stimulation at the onset of tremor only. Thus, this project will allow us to optimize DBS therapy in ET, by improving the longevity of implantable devices and avoiding the loss of efficacy previously reported

Eligibility Criteria:
Inclusion Criteria:

* Patients suffering from severe and disabling ET with serious impact on their quality of life (QoL).
* 18-70 years old
* Free of evolutive and untreated psychiatric disorder
* Tremor must be predominant in the upper limbs although it can affect the lower limbs, head and voice.
* Affiliation to a social security system
* Written informed consent signed by the participant and the investigator (prior to any examination required by research)

Exclusion Criteria:

* Parkinsonian tremor
* Pregnancy or lactating women
* Severe co-morbidity (cardiac, renal or respiratory failures, evolutive cancer)
* Impaired cognitive functions (score \<130 on Mattis scale).
* Patients with severe atrophy or lesions on MRI
* Depression (Beck \> 10)
* Participation in another clinical research for 18 months (after surgery)
The GABAergic Inhibitory System in Drug Resistant Epilepsy

This study aims to investigate the effect of lovastatin on neurotransmission and neuroinflammation in patients with temporal lobe onset drug resistant epilepsy.

Structure: (1) Visit 1: 3 consecutive days of physiologically probing drug/placebo intake, (2) Visit 2: Outcome measures and additional evaluations in the day after the last drug/placebo intake, (3) Washout period of 4 weeks, (4) 3 consecutive days of drug/placebo intake, (5) Visit 3: Outcome measures and additional evaluations in the day after the last placebo/drug intake.

This study investigates the potential therapeutic effects of lovastatin, a drug known for its anti-inflammatory and neuroprotective properties, in patients with temporal lobe drug-resistant epilepsy (DRE). Emerging evidence suggests that inflammation plays a significant role in epileptogenesis, and preclinical models of epilepsy have demonstrated the efficacy of statins in reducing seizure susceptibility.

This pilot, double-blinded, placebo-controlled crossover study included five participants with focal-onset DRE. The primary objectives were to evaluate the impact of lovastatin on cortical inhibition, oxidative stress, and seizure activity. Participants received 60 mg/day of lovastatin or placebo for a specified period, with treatment phases separated by a washout period.

Key assessments included magnetic resonance spectroscopy (MRS) to measure brain metabolites such as GABA, glutamate, and glutathione in the occipital cortex. Event-related potentials (ERP) were recorded during a facial recognition task to examine visual evoked potentials, while resting EEG was used to analyze interictal epileptiform discharges (IEDs).

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of pharmacoresistant epilepsy as defined by the International League Against Epilepsy,
* focal temporal lobe onset
* nonpregnant and nonlactating in women

Exclusion Criteria:

* history of cardiovascular or cerebrovascular disease,
* history of dyslipidemia, previous use of statins or a previously documented adverse reaction to statins,
* having any metal inside the head but outside the mouth,
* implanted devices such as cardiac pacemakers or cochlear implants,
* having a vagal nerve stimulation device and the presence of other comorbid neurologic conditions
A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

The purpose of this study is to show that high-dose quadrivalent seasonal influenza vaccine (HD QIV) given together with 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) does not induce lower antibody response against each of the 4 influenza vaccine strains, as compared to HD QIV given alone and further show that ExPEC9V given together with HD QIV does not induce lower antibody response against each of the vaccine O-serotype antigens, as compared to ExPEC9V given alone.


Eligibility Criteria:
Inclusion Criteria:

* Must be medically stable at the time of vaccination such that, according to the judgment of the investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol specified follow-up. A stable medical condition is defined as disease not requiring significant change in therapy during the 6 weeks before enrollment and when hospitalization for worsening of the disease is not anticipated. Participants will be included on the basis of physical examination, medical history, and vital signs performed between informed consent form (ICF) signature and vaccination
* Participant must be: a) postmenopausal (postmenopausal state is defined as no menses for 12 months without an alternative medical cause); and b) not intending to conceive by any methods
* Must sign an ICF indicating that the participant understands the purpose, procedures and potential risks and benefits of the study, and is willing to participate in the study
* Willing and able to adhere to the lifestyle restrictions specified in this protocol
* Agrees to not donate blood from the time of vaccination until 3 months after receiving the last dose of study vaccine

Exclusion Criteria:

* History of an underlying clinically significant acute or uncontrolled chronic medical condition or significant cognitive impairment or physical examination findings for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
* Known or suspected allergy or history of severe allergic reaction, anaphylaxis, or other serious adverse reactions to vaccines or vaccine excipients
* History of severe allergic reactions (for example anaphylaxis) to any component of the high-dose (HD) quadrivalent seasonal influenza vaccine, including egg protein, or following a previous dose of any influenza vaccine
* Has had major surgery (per the investigator's judgment) within 4 weeks before administration of the first study vaccine or will not have recovered from surgery per the investigator's judgment at time of vaccination
* History of acute polyneuropathy (for example, Guillain-Barré syndrome) or chronic inflammatory demyelinating polyneuropathy
A Study of Smoking Cessation Patterns in Participants Undergoing Lung Surgery

The purpose of this study is to assess the current smoking status and smoking cessation attempts among smokers or recent smoking quitters during the perioperative period, to describe postoperative pulmonary complications (PPCs) and other postoperative complications (PCs) following a lung surgery, and to describe the smoking cessation methods and services patients received from their health care professionals (HCPs) and participant's satisfaction among participants with lung cancer, chronic obstructive pulmonary disorder (COPD), a pulmonary lesion (example, nodule, or ground glass opacity) or other pulmonary conditions who are admitted to the thoracic surgical unit of the participating hospitals in China.


Eligibility Criteria:
Inclusion Criteria:

* Participants who have been scheduled for an elective lung surgery by the treating physician's judgement, due to the following conditions: known lung cancer, COPD, a pulmonary lesion (example. nodule, ground glass opacity) or other pulmonary conditions
* Smokers who are or were smoking on average no fewer than 5 cigarettes per day for equal or more than 3 years within 3 months prior to the scheduled surgery, or recent smoking quitters with a history of smoking on average no fewer than 5 cigarettes per day for equal or more than 3 years, who quit smoking between 3 months and 5 years prior to the scheduled surgery
* Being willing to participate the study and sign the participant informed consent form (ICF)

Exclusion Criteria:

* Participants who have emergency lung surgery due to accident or injury
* Participants are not likely to be able to complete the 6-month follow-up after the lung surgery
Neurotoxicity of Anesthesia in Middle Aged Patients

for the last 20 years, the increasing reports from non-human studies have raised suspicion that general anesthetics may cause neurotoxic changes in the developing brain that lead to adverse neurodevelopmental outcomes later in life.there are several case reports of reversible smell and taste dysfunction following exposure to general anesthesia suggesting a possible relationship between anesthetic agents and olfactory dysfunction.

this study is to assess the possible neurotoxicity of sevoflurane,isoflurane,and propofol based anesthesia guided by olfactory changes

the primary inhibitory neurotransmitter GABA is found in neuronal synapses involving olfactory bulb. So, the involvement of common GABA pathway implies a possible interaction of general anesthetics with olfactory function.

olfactory identification is an associative memory which is found to be facilitated by action of melatonin. involvement of GABA receptor in the transfer of light information from suprachiasmatic nuclei to pineal gland suggests possible interaction of melatonin and anesthetic agents.

the aim of the study is to evaluate the possible neurotoxicity of sevoflurane,isoflurane,and propofol based anesthesia guided by olfactory changes

Eligibility Criteria:
Inclusion Criteria:

* patients aged 18-50 years
* both sex
* American society of Anesthesiologists' physical status I and II
* elective surgery of duration 90-120 minutes

Exclusion Criteria:

* patients's refusal
* recent airway infection
* allergic rhinitis
* nasal polyps
* history of alcoholism
* smoking
* pregnancy
* menstruating female
* mental retardation
* psychiatric illness
* neurosurgical or oto-rhino-laryngeal surgery
* history of olfactory deficits or cognitive impairment
* CNS disease e.g. epilepsy
* history of first degree relative with alzheimer's disease,dementia, or cognitive dysfunction
* those who are unable to answer the tests themselves
Flexible Catheter for Insulin in Diabetes

Use of a flexible subcutaneous catheter improves comfort in patients with DKA compared to the usual treatment with a metal needle.

Assess whether the use of a flexible subcutaneous catheter improves comfort in patients with DKA compared to the usual treatment with a metal needle.

Compare the metabolic evolution of patients with DKA using a flexible subcutaneous catheter for insulin administration vs. a metal needle.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 5 to 18 years, admitted with diagnoses of DKA. DKA is defined when patients meets all the following biochemical baseline criteria (before initial hydration):
* Glucose\> 200 mg / dl
* pH \< 7.3
* Bicarbonate \< 15mmol/l.

Exclusion Criteria:

* Patients referred from another institution with a different treatment, and those who requires intensive care on admission.
Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T

This is a clinical research study of an investigational (FDA IND-BB 10091) treatment of subjects with castration-resistant prostate cancer resistant to Taxanes (docetaxel, cabazitaxel) and evidence of disease progression on androgen-axis inhibition and/or immunotherapy in the form of sipuleucel-T.

The treatment is being evaluated for its effect on tumor growth. It consists of the placement (implantation) of small beads that contain mouse renal adenocarcinoma cells (RENCA macrobeads). The cells in the macrobeads produce substances that have been shown to slow or stop the growth of tumors in experimental animals and veterinary patients. It has been tested in 31 human subjects with different types of cancers in a Phase I safety trial. Phase II studies in patients with colorectal, pancreatic or prostate cancers are in progress.


Eligibility Criteria:
Inclusion Criteria:

* Cancer of prostate
* Evidence of metastasis
* Failed available therapies
* Resolution of any toxic effects of previous therapies
* Performance status (ECOG PS) 0-2
* Adequate hematologic, coagulation (INR 2-3max), hepatic and renal function
* Life expectancy of 12 months
* Agrees to contraceptive use while on study if sexually active
* Sign informed consent document

Exclusion Criteria:

* Any condition presenting an unacceptably high anesthetic or surgical risk
* HIV positive
* Cognitive impairment such as to preclude informed consent
* Other surgical treatment, chemotherapy and radiation within four weeks of baseline
* Inadequate hematologic, coagulation (INR \>3), hepatic, renal function
* Hepatic blood flow abnormalities and/or large-volume ascites
* Concurrent cancer of any other type except skin cancer (excluding melanoma)
* History of allergic reactions to mouse antigens
* Active infection, congestive heart failure, unstable angina, serious cardiac arrhythmias, psychiatric illness, difficult social situations not permitting reliable participation, active bleeding
Music Application in Patients Undergoing Percutaneous Coronary Intervention

This study was planned to examine the effect of music application on recovery in patients undergoing coronary angiography (CAG) and to obtain the opinions of patients and nurses about music.This study was conducted to examine the effect of music application on recovery in patients undergoing CAG and to obtain the opinions of patients and nurses about music.The study was planned as a pre-test, post-test design, single-center, randomized controlled experimental study. The study is planned to be conducted in the CAG unit of a university hospital between July 2023 and December 2023, the study sample will be composed of a total of 210 individuals, 105 in each group (music applied group before and after the procedure = 105, control group = 105) To collect data in the study, the "Patient Information Form", Vital Signs Evaluation Form", "Numerical Rating Scale", State-Trait Anxiety Inventory, "Perianesthesia Comfort Scale" and "Patient Satisfaction Survey on Nursing Care Quality" were used.

In the study, before the patients in the music group (MG) who would undergo planned CAG listened to music, while the patients were in the ward before the procedure; Patient information form, vital signs registration form, numerical rating scale, state-trait anxiety scale were applied, then 15-20 minutes. Music prepared with expert suggestions (Rast, Acemasiran, and Huseyni modes) 15-20 min. was listened to. After the procedure, patients in MG are given 15-20 minutes before being discharged. music was played. Then, the vital signs registration form, Numerical Rating Scale, state-trait anxiety scale, Perianesthesia Comfort Scale, and Patient Satisfaction Survey on Nursing Care Quality were administered for the last time. The specified survey forms were applied to the patients in Control Group before and after the procedure, and they were not allowed to listen to music.

Eligibility Criteria:
Inclusion Criteria:

* being between the ages of 18-65,
* being literate,
* having no communication or hearing impairment or neurological-psychiatric disease,
* not taking sedatives before the procedure
* not having undergone PCI before
* being in the waiting room at least 20 minutes before the procedure.

Exclusion Criteria:

* Under the age of 18
* Do not speak Turkish
* Have a hearing problem
* Without a place and time orientation
* Have any psychiatric illness
* Using sedative or analgesic drugs in the last 24 hours
* To be intervened outside the femoral area
* Previous angiography procedure
* Non-volunteer individuals will not be included in the study